- Home
- PFL vs ANGO Comparison
PFL vs ANGO Comparison
Compare PFL & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFL | ANGO |
|---|---|---|
| Founded | 2003 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 374.5M | 400.8M |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | PFL | ANGO |
|---|---|---|
| Price | $8.38 | $13.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.33 |
| AVG Volume (30 Days) | 113.7K | ★ 513.0K |
| Earning Date | 01-01-0001 | 01-07-2026 |
| Dividend Yield | ★ 11.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,718,000.00 |
| Revenue This Year | N/A | $8.18 |
| Revenue Next Year | N/A | $5.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.73 |
| 52 Week Low | $6.98 | $8.27 |
| 52 Week High | $8.62 | $13.99 |
Technical Indicators
Market Signals| Indicator | PFL | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 58.95 |
| Support Level | $8.37 | $13.12 |
| Resistance Level | $8.42 | $13.70 |
| Average True Range (ATR) | 0.04 | 0.38 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 15.79 | 38.68 |
Price Performance
Historical ComparisonAbout PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.